Mayne Pharma Group (MYX) AGM 2026 summary

Opening remarks and agenda

• Meeting opened with acknowledgment of hybrid format, procedural instructions, and commenced at 10:00am Melbourne time, chaired by Professor Bruce Robinson.

• Board and executive team introduced, including recognition of retiring directors and thanks to outgoing Chair.

• Agenda included Chair's report, CFO's business update, Q&A, and voting on resolutions.

Financial performance review

• FY 2025 revenue grew 5% to AUD 408.1 million, gross margin expanded to 60.6%, and underlying EBITDA more than doubled to AUD 47 million.

• Operating cash flow from continuing operations improved to AUD 45.4 million, up 460%.

• 1H FY 2026 unaudited revenue was AUD 212.1 million (down 0.5%), gross margin rose to 66%, and underlying EBITDA was AUD 28.6 million, down 8%.

• Women's Health segment revenue up 25%, with NEXTSTELLIS showing strong growth; Dermatology margin improved despite generic competition.

• Segment highlights: Women's Health revenue up 2%, Dermatology gross margin up 12%, International gross profit up 6%.

Board and executive committee updates

• Frank Condella retired as Chair in January 2026; Anne Lockwood and Pat Blake to retire after mid-year results.

• Bruce Robinson reaffirmed commitment to strategy execution and governance.

• Ann Custin and David Petrie stood for re-election, highlighting their experience and commitment.